ProfoundBio's lead treatment candidate is aimed at ovarian and endometrial cancer and is in phase 2 clinical trials. Related Articles . Impinj cuts 10% of its staff in push to improve profitability ...

Danish biotech Genmab has agreed to buy privately owned U.S. cancer drug maker ProfoundBio for $1.8 billion, the two companies said on Wednesday.

Genmab said Wednesday it would acquire ProfoundBio for $1.8 billion, the latest in a string of 10-figure deals tied to the booming field of targeted chemotherapies.

ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple d ...

ProfoundBio also announced the addition of new board members, including Andrew Lam, managing director and head of biotech private equity at Ally Bridge Group, which led the financing round.New ...

Danish biotech Genmab will buy U.S.-based ProfoundBio for $1.8 billion in cash as it looks to bolster its pipeline of cancer treatments.

ProfoundBio actually lists its headquarters as Seattle, though it has strong China ties that make it a sort of U.S.-China hybrid. The company operates an R&D facility in the city of Eastern ...

WOODINVILLE, Wash. and SUZHOU, China, March 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical stage biotechnology company focused on the development of novel antibody-based therapeutics with ...

ProfoundBio is testing Rina-S in the second part of a phase 1/2 clinical trial in ovarian cancer and other FRα-expressing tumors. Genmab sees a future for the ADC in a range of FRα-expressing ...

ProfoundBio co-founders Dr. Baiteng Zhao and Dr. Tae H. Han recognized for building the state’s most valuable life science company in less than a decade SEATTLE--(BUSINESS WIRE)-- Life Science ...

Erin Lavelle, COO and CFO of ProfoundBio, said the funding "boosts our momentum." This story first appeared in the Puget Sound Business Journal. Biotech company ProfoundBio has raised a $112 ...